The Latest Breaking News from LLY

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in

Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster.

Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year

As Eli Lilly has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.

Eli Lilly stock rose Thursday despite lighter-than-expected sales of its weight-loss and diabetes drugs Zepbound and Mounjaro.

March S&P 500 E-Mini futures (ESH25) are up +0.05%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.08% this morning as investors awaited a new round of U.S. economic data, remarks from Federal Reserve officials, and an earnings report from “Magnificent Seven” member Amazon.

Eli Lilly's two major GLP-1 drugs have dominated headlines, but a slate of new treatments in development—and some already available—suggest a bright future.

Cool wholesale inflation numbers provide only slight relief before Wednesday's release of December Consumer Price Index data.